HIV-1 entry into cells is an attractive target for new antiviral agents. But will inhibitors aimed at the CCR5 co-receptor force HIV-1 to evolve more virulent forms? Other targets for entry ...

humanized monoclonal antibody ibalizumab (TNX-355), which blocks the human cellular CD4 receptor for HIV, is currently in phase 2 trials. The two cellular coreceptors CCR5 and CXCR4 are also being ...

The authors have requested a retraction of a paper that found people with the CCR5 Δ32 variant are more likely to die sooner. People with two copies of the Δ32 variant of the gene CCR5 have protection ...

Summary: Maraviroc is the first CCR5 coreceptor antagonist to receive marketing approval from the Food and Drug Administration (FDA) for the treatment of CCR5-tropic human immunodeficiency virus ...